Coastal Cancer Center

Located in Myrtle Beach, South Carolina, Coastal Cancer Center offers specialized care in oncology and hematology, focusing on comprehensive treatment for cancer and blood disorders. Coastal Cancer Center, founded in 1982, is dedicated to providing oncology and hematology care. It has remained consistent in its core mission without significant pivots in business strategy. The center is headquartered in Myrtle Beach, SC, and has conducted one deal as of May 3, 2023.

The founder's specific history is not documented, and there is no mention of previous companies. The most recent investment in Coastal Cancer Center occurred in May 2023, but financial terms were not disclosed. Coastal Cancer Center specializes in comprehensive oncology and hematology care, providing a range of medical services tailored to treat various forms of cancer and blood disorders. Their core offerings include medical oncology, hematology, chemotherapy administration, and diagnostic imaging services such as PET, CT, and X-ray.

The center is equipped with an on-site pharmacy to streamline prescription services and an in-house laboratory that enables immediate blood count results, facilitating prompt treatment decisions. Coastal Cancer Center serves a diverse client base, including both year-round residents and seasonal visitors in South Carolina. Their geographical market extends to the Grand Strand area, encompassing communities in Myrtle Beach, Conway, Loris, and Murrells Inlet, where they deliver patient-centered care in a supportive environment. Coastal Cancer Center generates revenue through direct patient transactions for their medical services, which include consultations, laboratory tests, imaging services, and chemotherapy treatments.

Patients typically engage with the center either through direct appointments or referrals from healthcare providers, facilitating a seamless experience in their cancer care journey. Revenue is primarily derived from fee-for-service models, with pricing structures aligned with the services rendered. The center's commitment to quality care is underscored through its Quality Oncology Practice Initiative certification, which maintains rigorous standards for service delivery. This operational framework allows Coastal Cancer Center to effectively serve its patient population while ensuring the sustainability of its business model.

In May 2023, OneOncology, LLC, a portfolio company of AmerisourceBergen Corporation, TPG, and Frist Cressey Ventures, acquired Coastal Cancer Center. This acquisition enables Coastal Cancer Center to pursue further growth and enhance patient care. Future initiatives may include the development of new treatment programs and improvements in existing medical offerings, although specific product launches and timelines have not been detailed. The acquisition will facilitate expansion efforts in the South Carolina region, allowing the center to amplify its service reach and enhance operational capabilities.